Diana M Eccles

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7150184/publications.pdf

Version: 2024-02-01

325 papers	37,780 citations	3731 89 h-index	3323 184 g-index
338 all docs	338 docs citations	338 times ranked	33696 citing authors

#	Article	IF	Citations
1	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	6.2	3,105
2	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	27.8	2,165
3	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
4	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 2002, 31, 55-59.	21.4	1,001
5	PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics, 2007, 39, 165-167.	21.4	858
6	Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation, 2008, 29, 1282-1291.	2.5	782
7	Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822.	6.3	753
8	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	27.8	737
9	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
10	Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genetics, 2010, 42, 504-507.	21.4	653
11	ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 873-875.	21.4	641
12	Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1748-1757.	1.6	641
13	Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 2006, 38, 1239-1241.	21.4	636
14	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
15	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
16	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
17	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
18	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	6.4	461

#	Article	IF	Citations
19	Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882.	21.4	460
20	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	21.4	434
21	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
22	Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet, The, 2003, 362, 39-41.	13.7	421
23	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
24	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
25	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
26	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
27	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
28	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
29	Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncology, The, 2018, 19, 169-180.	10.7	316
30	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
31	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
32	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
33	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193.	1.9	279
34	Psychosocial impact of breast/ovarian (BRCA 1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. British Journal of Cancer, 2004, 91, 1787-1794.	6.4	276
35	Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine, 2008, 359, 2567-2578.	27.0	273
36	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265

#	Article	IF	Citations
37	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	6.2	257
38	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
39	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research, 2014, 16, 442.	5.0	252
40	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
41	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480.	3.2	232
42	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	10.7	232
43	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute, 2018, 110, 855-862.	6.3	225
44	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
45	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	13.7	220
46	Germline RAD51C mutations confer susceptibility to ovarian cancer. Nature Genetics, 2012, 44, 475-476.	21.4	219
47	Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature, 2013, 493, 406-410.	27.8	218
48	Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nature Genetics, 2013, 45, 295-298.	21.4	208
49	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
50	A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis. Cancer Prevention Research, 2011, 4, 655-665.	1.5	193
51	Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). Journal of the National Cancer Institute, 2006, 98, 535-544.	6.3	191
52	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
53	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
54	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168

#	Article	IF	Citations
55	Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. Journal of Medical Genetics, 2008, 45, 425-431.	3.2	167
56	Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. British Journal of Cancer, 2004, 91, 1155-1159.	6.4	161
57	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Research, 2017, 19, 58.	5.0	161
58	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
59	Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18â€“40 Years at Diagnosis: The POSH Study. Journal of the National Cancer Institute, 2013, 105, 978-988.	6.3	156
60	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
61	Comparative PRKAR1A genotypeâ€“phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14222-14227.	7.1	152
62	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
63	Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System. Journal of Clinical Oncology, 2005, 23, 5588-5596.	1.6	151
64	Further observations on LKB1/STK11 status and cancer risk in Peutzâ€“Jeghers syndrome. British Journal of Cancer, 2003, 89, 308-313.	6.4	148
65	Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics Journal, 2015, 15, 84-94.	2.0	148
66	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420.	1.6	148
67	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	1.9	148
68	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
69	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
70	Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Human Molecular Genetics, 1998, 7, 1907-1912.	2.9	142
71	Therapeutic Targeting of Integrin Î±vÎ²6 in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	132
72	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology, 2013, 31, 49-57.	1.6	126

#	Article	IF	Citations
73	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	3.2	121
74	Prediction of singleâ€nucleotide substitutions that result in exon skipping: identification of a splicing silencer inBRCA1exon 6. Human Mutation, 2011, 32, 436-444.	2.5	120
75	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
76	Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. American Journal of Human Genetics, 2003, 72, 1023-1028.	6.2	119
77	Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Research, 2006, 66, 1866-1872.	0.9	119
78	Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH. Gastroenterology, 2009, 137, 489-494.e1.	1.3	114
79	A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655.	2.8	111
80	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
81	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
82	A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. Journal of Medical Genetics, 2010, 47, 771-774.	3.2	102
83	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
84	19p13.1 Is a Triple-Negativeâ€“Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
85	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	2.9	99
86	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
87	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. Journal of Medical Genetics, 2012, 49, 525-532.	3.2	97
88	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
89	Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer, 2015, 15, 936.	2.6	96
90	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249.	10.7	95

#	Article	IF	Citations
91	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
92	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
93	Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Journal of Clinical Oncology, 2015, 33, 3591-3597.	1.6	91
94	A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncology, 2019, 5, 1718.	7.1	91
95	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	6.3	90
96	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
97	Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Research, 2002, 4, R14.	5.0	89
98	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
99	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Human Mutation, 2010, 31, E1484-E1505.	2.5	86
100	BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. British Journal of Cancer, 2012, 106, 1234-1238.	6.4	85
101	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU International, 2011, 107, 28-39.	2.5	83
102	Machine learning approaches for the discovery of gene-gene interactions in disease data. Briefings in Bioinformatics, 2013, 14, 251-260.	6.5	81
103	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
104	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	3.2	80
105	Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. British Journal of Cancer, 2007, 96, 718-724.	6.4	79
106	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	21.4	78
107	A Dominantly Inherited 5â€² UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. American Journal of Human Genetics, 2018, 103, 213-220.	6.2	78
108	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77

#	Article	IF	Citations
109	Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer. Annals of Surgery, 2017, 266, 165-172.	4.2	77
110	The DNMT3B Câ†'T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Research, 2004, 6, R390-4.	5.0	75
111	Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032.	7.0	75
112	Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 827-831.	7.1	73
113	Obesity and the outcome of young breast cancer patients in the UK: the POSH study. Annals of Oncology, 2015, 26, 101-112.	1.2	72
114	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71
115	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
116	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of Medical Genetics, 2011, 48, 520-522.	3.2	69
117	No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Letters, 2006, 240, 195-197.	7.2	68
118	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
119	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
120	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
121	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 2010, 47, 99-102.	3.2	61
122	Non-Uptake of Predictive Genetic Testing for BRCA1/2 among Relatives of Known Carriers: Attributes, Cancer Worry, and Barriers to Testing in a Multicenter Clinical Cohort. Genetic Testing and Molecular Biomarkers, 2004, 8, 23-29.	1.7	59
123	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
124	Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. British Journal of Cancer, 2014, 110, 230-241.	6.4	56
125	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine, 2015, 2, 681-689.	6.1	56
126	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56

#	Article	IF	Citations
127	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	5.0	56
128	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Human Mutation, 2008, 29, 1292-1303.	2.5	54
129	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
130	RNA analysis reveals splicing mutations and loss of expression defects inMLH1 andBRCA1. Human Mutation, 2004, 24, 272-272.	2.5	52
131	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. Familial Cancer, 2017, 16, 433-440.	1.9	52
132	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Frontiers in Pharmacology, 2017, 8, 582.	3.5	52
133	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
134	Evaluation ofRAD50 in familial breast cancer predisposition. International Journal of Cancer, 2006, 118, 2911-2916.	5.1	51
135	Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. Gut, 2008, 57, 1252-1255.	12.1	51
136	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Scientific Reports, 2018, 8, 6574.	3.3	51
137	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	3.2	50
138	The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Research, 2008, 10, R108.	5.0	49
139	Information requirements of young women with breast cancer treated with mastectomy or breast conserving surgery: A systematic review. Breast, 2016, 25, 1-13.	2.2	49
140	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
141	Risk of Ovarian Cancer and the NF-ÎºB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.9	48
142	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
143	Evaluation of Fanconi Anemia genes in familial breast cancer predisposition. Cancer Research, 2003, 63, 8596-9.	0.9	48
144	Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer, 2007, 7, 160.	2.6	47

#	Article	IF	Citations
145	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
146	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
147	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
148	Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. Advances in Therapy, 2016, 33, 129-150.	2.9	46
149	Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 65-72.	1.9	45
150	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	1.9	45
151	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
152	Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. Npj Genomic Medicine, 2018, 3, 7.	3.8	44
153	Identification of Inherited Genetic Variations Influencing Prognosis in Early-Onset Breast Cancer. Cancer Research, 2013, 73, 1883-1891.	0.9	42
154	A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis. PLoS ONE, 2014, 9, e101488.	2.5	42
155	Geneâ€“gene interactions in breast cancer susceptibility. Human Molecular Genetics, 2012, 21, 958-962.	2.9	41
156	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	5.0	41
157	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
158	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
159	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
160	Apoptosis, ageing and cancer susceptibility. British Journal of Cancer, 2003, 88, 487-490.	6.4	37
161	Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer, 2006, 6, 80.	2.6	37
162	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37

#	Article	IF	Citations
163	Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncology, The, 2005, 6, 705-711.	10.7	36
164	Acute Chemotherapyâ€“Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038.	7.0	36
165	Analysis of RAD51D in Ovarian Cancer Patients and Families with a History of Ovarian or Breast Cancer. PLoS ONE, 2013, 8, e54772.	2.5	36
166	Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. Oncogene, 2000, 19, 4170-4173.	5.9	35
167	Accurate Prediction of BRCA1 and BRCA2 Heterozygous Genotype Using Expression Profiling after Induced DNA Damage. Clinical Cancer Research, 2006, 12, 3896-3901.	7.0	34
168	Prevalence of Adenomas and Hyperplastic Polyps in Mismatch Repair Mutation Carriers Among CAPP2 Participants: Report by the Colorectal Adenoma/Carcinoma Prevention Programme 2. Journal of Clinical Oncology, 2008, 26, 3434-3439.	1.6	34
169	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
170	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
171	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. Journal of Medical Genetics, 2020, 57, 509-518.	3.2	33
172	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. Journal of Medical Genetics, 2015, 52, 224-230.	3.2	32
173	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. Journal of Medical Genetics, 2019, 56, 347-357.	3.2	32
174	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
175	Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes. Human Mutation, 2016, 37, 331-336.	2.5	31
176	Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. Journal of Clinical Pathology, 2012, 65, 403-408.	2.0	30
177	Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. Journal of Medical Genetics, 2020, 57, 829-834.	3.2	30
178	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
179	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
180	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28

#	Article	IF	Citations
181	Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. Journal of Medical Genetics, 2021, 58, 297-304.	3.2	28
182	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	6.4	27
183	An evaluation of the prognostic model PREDICT using the POSH cohort of women aged â©½40 years at breast cancer diagnosis. British Journal of Cancer, 2015, 112, 983-991.	6.4	27
184	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Scientific Reports, 2013, 3, 2059.	3.3	26
185	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
186	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
187	Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. Journal of Medical Genetics, 2019, 56, 209-219.	3.2	26
188	Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 211-4.	2.5	26
189	A Germ Line Mutation in the Death Domain of DAPK-1 Inactivates ERK-induced Apoptosis. Journal of Biological Chemistry, 2007, 282, 13791-13803.	3.4	25
190	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	5.0	25
191	Family history and outcome of young patients with breast cancer in the UK (POSH study). British Journal of Surgery, 2015, 102, 924-935.	0.3	25
192	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
193	Familial Adenomatous Polyposis-Associated Desmoids Display Significantly More Genetic Changes than Sporadic Desmoids. PLoS ONE, 2011, 6, e24354.	2.5	24
194	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
195	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
196	Ethical, Social and Economic Issues in Familial Breast Cancer: A Compilation of Views from the E.C. Biomed II Demonstration Project. Disease Markers, 1999, 15, 125-131.	1.3	23
197	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
198	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23

#	Article	IF	Citations
199	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
200	Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients. British Journal of Cancer, 2020, 122, 1618-1629.	6.4	23
201	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
202	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	5.0	22
203	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
204	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
205	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€"Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
206	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	6.2	21
207	Genetic testing in a cohort of young patients with HER2-amplified breast cancer. Annals of Oncology, 2016, 27, 467-473.	1.2	21
208	Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer. Patient Education and Counseling, 2018, 101, 779-788.	2.2	21
209	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
210	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. Breast, 2019, 45, 1-6.	2.2	21
211	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget, 2017, 8, 14525-14536.	1.8	21
212	Mutation scanning by meltMADGE: Validations using BRCA1 and LDLR, and demonstration of the potential to identify severe, moderate, silent, rare, and paucimorphic mutations in the general population. Genome Research, 2005, 15, 967-977.	5.5	20
213	First case report of Muirâ€"Torre syndrome associated with non-small cell lung cancer. Familial Cancer, 2009, 8, 359-362.	1.9	20
214	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20
215	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 2015, 17, 18.	5.0	20
216	Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. Annals of Oncology, 2004, 15, iv133-iv138.	1.2	19

#	Article	IF	Citations
217	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
218	Highâ€throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	3.0	19
219	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. JCO Precision Oncology, 2018, 2, 1-42.	3.0	19
220	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
221	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
222	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Research and Treatment, 2016, 157, 117-131.	2.5	18
223	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
224	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. Nature Communications, 2017, 8, 1632.	12.8	18
225	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
226	Increased circulating resistin levels in early-onset breast cancer patients of normal body mass index correlate with lymph node negative involvement and longer disease free survival: a multi-center POSH cohort serum proteomics study. Breast Cancer Research, 2018, 20, 19.	5.0	18
227	Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). Journal of Pathology: Clinical Research, 2019, 5, 189-198.	3.0	18
228	Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. International Journal of Radiation Oncology Biology Physics, 2004, 58, 470-478.	0.8	17
229	A novel duplication polymorphism in the FANCApromoter and its association with breast and ovarian cancer. BMC Cancer, 2005, 5, 43.	2.6	17
230	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Clinical Pharmacology and Therapeutics, 2020, 108, 661-670.	4.7	17
231	Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. Familial Cancer, 2009, 8, 479-482.	1.9	16
232	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
233	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nature Communications, 2014, 5, 4051.	12.8	16
234	Consortium analysis of gene and geneâ€"folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16

#	Article	IF	Citations
235	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
236	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
237	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
238	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
239	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	2.4	15
240	Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY). Journal of Medical Genetics, 2020, 57, 226-236.	3.2	15
241	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15
242	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
243	Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis. International Journal of Cancer, 2019, 145, 3207-3217.	5.1	14
244	Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer. JCO Precision Oncology, 2020, 4, 472-485.	3.0	14
245	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
246	Support Vector Machine Classifier for Estrogen Receptor Positive and Negative Early-Onset Breast Cancer. PLoS ONE, 2013, 8, e68606.	2.5	13
247	Variation in NF-Î°B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
248	Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1018-1024.	2.5	13
249	Mammographic surveillance in women aged 35â€“39 at enhanced familial risk of breast cancer (FH02). Familial Cancer, 2014, 13, 13-21.	1.9	13
250	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. Journal of Medical Genetics, 2022, 59, 115-121.	3.2	13
251	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
252	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	2.5	12

#	Article	IF	Citations
253	Mutation and association analysis of GEN1 in breast cancer susceptibility. Breast Cancer Research and Treatment, 2010, 124, 283-288.	2.5	12
254	The Influence of Common Polymorphisms on Breast Cancer. Cancer Treatment and Research, 2010, 155, 15-32.	0.5	12
255	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
256	Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. Clinical Cancer Research, 2015, 21, 4086-4096.	7.0	12
257	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	6.4	12
258	Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers. Journal of Pathology: Clinical Research, 2020, 6, 146-153.	3.0	12
259	Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). Genetics in Medicine, 2022, 24, 1867-1877.	2.4	12
260	BRCA1 mutation and neuronal migration defect: implications for chemoprevention. Journal of Medical Genetics, 2005, 42, e42-e42.	3.2	11
261	Identification of personal risk of breast cancer: genetics. Breast Cancer Research, 2008, 10, S12.	5.0	11
262	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	2.5	11
263	Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations. Supportive Care in Cancer, 2019, 27, 297-309.	2.2	11
264	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
265	Renewed: Protocol for a randomised controlled trial of a digital intervention to support quality of life in cancer survivors. BMJ Open, 2019, 9, e024862.	1.9	10
266	Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
267	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	2.4	10
268	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
269	Psychosocial impact of undergoing prostate cancer screening for men with <scp>BRCA</scp>1 or <scp>BRCA</scp>2 mutations. BJU International, 2019, 123, 284-292.	2.5	9
270	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9

#	Article	IF	Citations
271	Risk Estimation as a Decision-Making Tool for Genetic Analysis of the Breast Cancer Susceptibility Genes. Disease Markers, 1999, 15, 53-65.	1.3	8
272	Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. Oncotarget, 2018, 9, 4249-4257.	1.8	8
273	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	6.4	7
274	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
275	Paucimorphic Alleles versus Polymorphic Alleles and Rare Mutations in Disease Causation: Theory, Observation and Detection. Current Genomics, 2004, 5, 431-438.	1.6	7
276	Genome-wide association of breast cancer: composite likelihood with imputed genotypes. European Journal of Human Genetics, 2011, 19, 194-199.	2.8	6
277	Analysis of KLLN as a high-penetrance breast cancer predisposition gene. Breast Cancer Research and Treatment, 2012, 134, 543-547.	2.5	6
278	Deep sequencing reveals the mitochondrial DNA variation landscapes of breast-to-brain metastasis blood samples. Mitochondrial DNA Part A: DNA Mapping, Sequencing, and Analysis, 2018, 29, 703-713.	0.7	6
279	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
280	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
281	Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors. Breast Care, 2022, 17, 208-223.	1.4	6
282	Economic and Practical Factors in Diagnosing HNPCC Using Clinical Criteria, Immunohistochemistry and Microsatellite Instability Analysis. Hereditary Cancer in Clinical Practice, 2004, 2, 175.	1.5	5
283	Composite likelihood-based meta-analysis of breast cancer association studies. Journal of Human Genetics, 2011, 56, 377-382.	2.3	5
284	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 2016, 10, 608.	1.1	5
285	â€œItâ€™s Like We Donâ€™t Existâ€: Tailoring Education for Young Women Undergoing Surgery for Early-Stage Breast Cancer. Oncology Nursing Forum, 2018, 45, 165-175.	1.2	5
286	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
287	Hereditary haemochromatosis should be more widely known about. BMJ: British Medical Journal, 1999, 318, 1486-1486.	2.3	5
288	Genetic testing and clinical management practices for variants in non-BRCA1/2 breast (and/or ovarian) cancer susceptibility genes: An international survey by the Enigma Clinical Working Group.. Journal of Clinical Oncology, 2018, 36, 1539-1539.	1.6	5

#	Article	IF	Citations
289	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	2.5	5
290	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
291	Quantifying prediction of pathogenicity for within-codon concordance (PM5) using 7541 functional classifications of BRCA1 and MSH2 missense variants. Genetics in Medicine, 2022, 24, 552-563.	2.4	5
292	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. Genetics in Medicine, 2022, 24, 41-50.	2.4	5
293	Prediction of Genetic Risks from Segregation Analyses of Morbid Risks. Human Heredity, 1994, 44, 52-55.	0.8	4
294	Genetic testing for BRCA1 mutation in the UK. Lancet, The, 2003, 361, 178-179.	13.7	4
295	Optimal Selection of Individuals for BRCA Mutation Testing. Journal of Clinical Oncology, 2006, 24, 3311-3311.	1.6	4
296	UK recommendations forSDHAgermline genetic testing and surveillance in clinical practice. Journal of Medical Genetics, 2023, 60, 107-111.	3.2	4
297	Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing. British Journal of Cancer, 2022, 127, 1116-1122.	6.4	4
298	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
299	Primary Clear Cell Microcystic Adenoma of the Sinonasal Cavity: Pathological or Fortuitous Association?. Case Reports in Pathology, 2017, 2017, 1-5.	0.3	3
300	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	2.5	3
301	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
302	Abstract B046: Therapeutic targeting of integrin Î±vÎ²6 in high-risk breast cancer. , 2013, , .		3
303	Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy. Hereditary Cancer in Clinical Practice, 2010, 8, O5.	1.5	2
304	Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention. Current Drug Targets, 2011, 12, 1974-1982.	2.1	2
305	Response: Table 1.. Journal of the National Cancer Institute, 2016, 108, djw173.	6.3	2
306	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2

#	Article	IF	Citations
307	Abstract 2671: CYP2D6 polymorphisms are not associated with tamoxifen outcome in premenopausal women with ER positive breast cancer of the POSH cohort. , 2012, , .		2
308	A phase I and pharmacology study of GR63178A, a water-soluble analogue of mitoquidone. Cancer Chemotherapy and Pharmacology, 1992, 29, 375-378.	2.3	1
309	Familial Cancer (special issue) Breast Cancer Treatment and Genetics. Familial Cancer, 2006, 5, 127-128.	1.9	1
310	Quantifying the cumulative effect of lowâ€penetrance genetic variants on breast cancer risk. Molecular Genetics & Genomic Medicine, 2015, 3, 182-188.	1.2	1
311	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Obstetrical and Gynecological Survey, 2017, 72, 338-340.	0.4	1
312	Hereditary Breast and Ovarian Cancer Testing in the Genomic Era. JAMA Oncology, 2019, 5, 58.	7.1	1
313	Associations of a breast cancer polygenic risk score with tumor characteristics and survival.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	1
314	Referral criteria for cancer genetics clinics. , 2002, , 157-165.		0
315	Breast cancer: genetics. Menopause International, 2008, 14, 183-183.	1.6	0
316	A review of the online prognositc model predict using the POSH cohort (women aged â‰40 years at) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	0
317	Genetic testing for young women with breast cancer â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e183.	10.7	0
318	Abstract 3351: Assessment of tamoxifen drug compliance by serum metabolite profiling in premenopausal breast cancer patients.. , 2013, , .		0
319	Abstract A35: SMARCE1 mutations cause inherited multiple spinal meningiomas. , 2013, , .		0
320	Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer. , 2014, , .		0
321	Abstract P4-12-03: Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes. , 2015, , .		0
322	Abstract 1924: Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. , 2015, , .		0
323	Abstract 2029: A high ratio of tamoxifen metabolite E to tamoxifen is associated with an increased risk of breast cancer recurrences in premenopausal women. , 2016, , .		0
324	Abstract 3451: Breast cancer risk factor associations by loss of E-cadherin tumor tissue expression: A pooled analysis of 5,896 cases in 12 studies from the Breast Cancer Association Consortium (BCAC). , 2016, , .		0

#	Article	IF	Citations
325	Abstract 2258: Genome-wide association studies of breast cancer prognosis. , 2017, , .		0